Drug Trial Radar · NCT06058299
Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis
Last checked: Nov 19, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
309
Actual
Start
Oct 31, 2023
Primary completion
Dec 27, 2024
Study completion Feb 2027
Sponsor
- Lead sponsor
- Global Alliance for TB Drug DevelopmentAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate 3 dose levels of TBAJ876 for 8 weeks in combination with pretomanid and linezolid, compared to 8 weeks of Isoniazid, rifampicin, pyrazinamide and ethambutol (2HRZE), in adult participants with newly diagnosed, smear-positive, pulmonary drug sensitive tuberculosis (DS-TB). The main questions the trial aims to answer are: * What is the optimal dose of TBAJ876 to continue further in development. * What is the bactericidal activity of bedaquiline with pretomanid and linezolid (B-Pa-L) compared to 2HRZE and TBAJ876-Pa-L over 8 weeks * What is the efficacy and safety of the 26-week B-Pa-L regimen compared with the SOC (2HRZE/4HR) in participants with DS-TB. Participants will be seen regularly during treatment (up to 26 weeks) and follow-up (52 weeks post treatment) for safety and efficacy assessments, including but not limited to: * Safety labs, ECGs, vital signs, physical exams, PK sampling, neuropathy assessments and adverse event monitoring * Sputum collection
Conditions
- Pulmonary TB
- Pulmonary Tuberculosis
- Drug Sensitive Tuberculosis
Interventions
sorfequilineDrug
tablet
PretomanidDrug
tablet
LinezolidDrug
tablet
BedaquilineDrug
tablet
HRZEDrug
fixed doe combination tablets
HRDrug
fixed dose combination tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants With Stable Sputum Conversion by 8 Weeks,Time frame: Through 8 weeks of treatment
Locations
22 sites in 5 countries. Site status is shown where the registry gives one.
National Center for Tuberculosis and Lung Diseases
Tbilisi, Georgia
Care Clinical Trial Group Inc.
Dasmariñas, Philippines
Tropical Disease Foundation
Makati City, Philippines
Lung Center of the Philippines
Quezon City, Philippines
Madibeng Centre for Research
Brits, South Africa
TASK Brooklyn
Cape Town, South Africa
University of Cape Town Lung Institute (UCTLI)
Cape Town, South Africa
Desmond Tutu Health Foundation
Cape Town, South Africa
Enhancing Care Foundation
Durban, South Africa
Synergy Biomed Research Institute (SBRI)
East London, South Africa
TASK Eden
George, South Africa
TB and HIV Investigative Network (THINK)
Hillcrest, South Africa
WITS, Clinical HIV Research Unit (CHRU) Themba Lethu Clinic, Helen Joseph Hospital
Johannesburg, South Africa
Perinatal HIV Research Unit (PHRU)
Klerksdorp, South Africa
Isango Lethemba TB Research Unit
Port Elizabeth, South Africa
The Aurum Institute
Rustenburg, South Africa
Setshaba Research Centre
Soshanguve, Gauteng, South Africa
NIMR-MBEYA Medical Research Center
Mbeya, Tanzania
Kilimanjaro Christian Medical Centre
Moshi, Tanzania
National Institute for Medical Research (NIMR)
Mwanza, Tanzania
Case Western Reserve University- Research collaboration Uganda
Kampala, Uganda
Joint Clinical Research Centre (JCRC)
Kampala, Uganda
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.